Chimeric antigen receptor (CAR) based immunotherapies offer a novel and rapidly developing technology that has great potential to ameliorate human disease. One fundamental challenge in the successful development and clinical application of CAR T-cells is the need to better understand the in vivo behaviour of adoptively infused cells. We aim to develop novel 18F-labelled PET tracers to dynamically track the persistence, migration, proliferation, and final fate of the infused CAR T-cells on a patient-by-patient basis. Thus, the new cell tracking probe would provide early insight into the safety, mechanism of action, and efficacy of CAR T-cell therapies.
 Wilkie, S. et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 2012, 1059–1070;
 Wilkie S. et al. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem. 2010, 285, 25538–25544;
 Shanafelt, A. B., et al. An immune cell-selective interleukin 4 agonist. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 9454–9458.